Screener
Vir Biotechnology, Inc. VIR Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
FAQ
- What is Vir Biotechnology, Inc.'s total equity?
- Vir Biotechnology, Inc. (VIR) reported total equity of $982.49M in Q2 2026.
- How has Vir Biotechnology, Inc.'s total equity changed year-over-year?
- Vir Biotechnology, Inc.'s total equity increased by 3.7% year-over-year, from $947.47M to $982.49M.
- What is the long-term trend for Vir Biotechnology, Inc.'s total equity?
- Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s total equity has grown at a 1.3% compound annual growth rate (CAGR), from $716.85M to $765.28M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Vir Biotechnology, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude